article thumbnail

Lilly buys into MiNA’s protein-boosting RNA tech in $1.25bn deal

pharmaphorum

UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in on the action. . The post Lilly buys into MiNA’s protein-boosting RNA tech in $1.25bn deal appeared first on.

RNA 76
article thumbnail

Laronde sets out to advance Endless RNA: ‘eRNA therapeutics have the potential to be an essential and widespread class of medicines’

BioPharma Reporter

Flagship Pioneering has unveiled Laronde: a platform company developing Endless RNA.

RNA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

smartRNA project joins BII Bio Studio programme

Drug Discovery World

A project focused on developing a small RNA-based platform technology for treating monogenic diseases, smartRNA, has joined the BioInnovation Institute’s (BII) Bio Studio programme. The technology has platform potential, as it leverages a universal small RNA pathway to target generic mRNA features.

RNA 52
article thumbnail

Scientists engineer safe, virus-resistant E coli for research

Drug Discovery World

In a step forward for genetic engineering and synthetic biology, US researchers have modified E coli bacteria to be immune to infection by all natural viruses tested so far. Genetic engineering The findings build on earlier efforts by genetic engineers, which involved genetically reprogramming E.

article thumbnail

mRNA prostate cancer drug successfully engaged CD3 T cells

Drug Discovery World

By building and iterating on RNA sequences through the CodonCracker software and the Nutcracker Manufacturing Unit, Nutcracker reported that its scientists engineered a group of molecules with attenuated PSMA and CD3 (cluster of differentiation 3) binding to mitigate on-target, off-tumour binding and target-independent T cell activation.

article thumbnail

Genetic eraser: Newly developed technology precisely and rapidly degrades targeted proteins

Scienmag

Credit: Masato Kanemaki Researchers can now more accurately and precisely target specific proteins in yeast, mammalian cells and mice to study how knocking down specific protein traits can influence physical manifestation in a cell or organism. “Conditional gene knockout and small interfering RNA […].

Protein 98
article thumbnail

Targovax announces plans to rebrand as Circio

Pharmaceutical Technology

Targovax has unveiled plans to rebrand as Circio , reflecting its strategic shift to focus on expediting the development of its innovative circular RNA (circRNA) platform. Initially reported in 2011, CircRNA is a naturally occurring class of RNA.